Ann: OncoSil AGM CEO Presentation, page-74

suzuki,

I back up any statement of fact with a citation, so that anyone can check the source and whether that source is credible.

you cannot come here with unsubstantiated information about Panco showing something that LAPACT doesn't show without substantiating that information.
I'm going to call it out every time you do!

As per previously cited sources, occurrence of adverse events in the Gem+abr (LAPACT) and Gem+abr+oncosil (PANCO) trials.

		LAPACT	PANCO
1	Anaemia	46	30
2	Neutropenia	42	46
3	Throbocytopenia	25	26
4	Abdominal pain	18	54
5	Constipation	30	48
6	Diarrhoea	45	60
7	Nausea	44	60
8	Vomiting	28	34
9	Fatigue	50	78
10	Perpheral Oedema	44	50
11	Pyrexia	38	34
12	Weight Loss	11	28
13	Decreased Appetite	43	38
14	Hypokalaemia	13	20
15	Peripheral Neuropathy	28	36
16	Alopecia	54	42
17	Rash	8	26
18
19	AVERAGE	33	42

You see, with the above information I can substantiate a claim that there is no difference in adverse effects between LAPACT and Panco or that under Oncosil, patients are more likely to suffer (I can make that second claim stronger with a statistical analysis).

Your turn...